JP2023537534A5 - - Google Patents
Info
- Publication number
- JP2023537534A5 JP2023537534A5 JP2023510439A JP2023510439A JP2023537534A5 JP 2023537534 A5 JP2023537534 A5 JP 2023537534A5 JP 2023510439 A JP2023510439 A JP 2023510439A JP 2023510439 A JP2023510439 A JP 2023510439A JP 2023537534 A5 JP2023537534 A5 JP 2023537534A5
- Authority
- JP
- Japan
- Prior art keywords
- epitope
- fragment
- antibody
- polyspecific
- polyspecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBPCT/GB2020/051959 | 2020-08-14 | ||
| PCT/GB2020/051959 WO2021032963A1 (en) | 2019-08-16 | 2020-08-14 | Therapeutic uses of anti-tcr delta variable 1 antibodies |
| GBGB2102224.9A GB202102224D0 (en) | 2021-02-17 | 2021-02-17 | Anti-TRC delta variable 1 antibodies |
| GB2102222.3 | 2021-02-17 | ||
| GB2102224.9 | 2021-02-17 | ||
| GBGB2102222.3A GB202102222D0 (en) | 2021-02-17 | 2021-02-17 | Multispecific anti-TCR delta variable 1 antibodies |
| PCT/IB2021/057509 WO2022034562A1 (en) | 2020-08-14 | 2021-08-14 | Multispecific anti-tcr delta variable 1 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023537534A JP2023537534A (ja) | 2023-09-01 |
| JP2023537534A5 true JP2023537534A5 (cg-RX-API-DMAC7.html) | 2024-08-21 |
| JP7847579B2 JP7847579B2 (ja) | 2026-04-17 |
Family
ID=80247426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023510439A Active JP7847579B2 (ja) | 2020-08-14 | 2021-08-14 | 多特異性抗tcrデルタ可変1抗体 |
Country Status (18)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2943063T5 (en) | 2020-08-14 | 2026-05-05 | Gammadelta Therapeutics Ltd | Multispecific anti-tcr delta variable 1 antibodies |
| EP4544302A1 (en) * | 2022-06-23 | 2025-04-30 | LAVA Therapeutics N.V. | Assay for t cell dependent multispecific compounds |
| EP4680729A1 (en) * | 2023-03-17 | 2026-01-21 | Legend Biotech Ireland Limited | Methods of culturing v delta 1 t cells |
| WO2025147597A1 (en) * | 2024-01-05 | 2025-07-10 | Eugit Therapeutics, Inc. | Targeting payloads |
| WO2025191133A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Il-21 muteins, fusion proteins comprising the same and uses thereof |
| WO2025191136A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof |
| WO2026026858A1 (en) * | 2024-07-30 | 2026-02-05 | Biomap (Suzhou) Intelligent Technology Limited | Dsg2 antibody and uses thereof |
| WO2026087748A1 (en) | 2024-10-24 | 2026-04-30 | Avidicure Ip B.V. | Multispecific antigen binding proteins for the expansion of γδ t cells and use thereof |
| WO2026087747A1 (en) | 2024-10-24 | 2026-04-30 | Avidicure Ip B.V. | Multispecific antigen binding proteins for tumor-targeting of γδ1 t cells and use thereof |
| US20260152558A1 (en) * | 2024-11-27 | 2026-06-04 | Gammadelta Therapeutics Ltd | Multispecific anti-tcr delta variable 1 antibodies |
| WO2026152120A2 (en) | 2025-01-13 | 2026-07-16 | HCW Biologics, Inc. | Chimeric polypeptides and uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2546268A1 (en) | 2011-07-13 | 2013-01-16 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Internalising immunoglobulin |
| WO2015063069A1 (en) * | 2013-10-28 | 2015-05-07 | Benjamin Felder | Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors |
| GB201506423D0 (en) * | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| JP6799895B2 (ja) | 2015-06-09 | 2020-12-16 | リンファクト−リンフォサイト アクティベイション テクノロジーズ エス.エー. | TCRγδ+T細胞の生産方法 |
| US10946095B2 (en) | 2015-09-02 | 2021-03-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT) |
| CN108473958A (zh) | 2015-10-30 | 2018-08-31 | 癌症研究技术有限公司 | 非造血组织驻留γδT细胞的扩增及这些细胞的用途 |
| CN118421557A (zh) | 2016-05-12 | 2024-08-02 | 阿迪塞特治疗公司 | 选择性扩增γδT细胞群的方法及其组合物 |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| EP3490675A4 (en) | 2016-07-29 | 2020-07-29 | New York University | T GAMMA DELTA LYMPHOCYTES USED AS A TARGET FOR THE TREATMENT OF SOLID TUMORS |
| US10546518B2 (en) | 2017-05-15 | 2020-01-28 | Google Llc | Near-eye display with extended effective eyebox via eye tracking |
| WO2019005637A2 (en) | 2017-06-25 | 2019-01-03 | Systimmune, Inc. | MULTIPECIFIC ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF |
| WO2019147735A1 (en) | 2018-01-23 | 2019-08-01 | New York University | Antibodies specific to delta 1 chain of t cell receptor |
| JP7457007B2 (ja) * | 2018-09-19 | 2024-03-27 | ラヴァ・セラピューティクス・エヌ・ヴイ | 二重作用CD1d免疫グロブリン |
| GB201818243D0 (en) | 2018-11-08 | 2018-12-26 | Gammadelta Therapeutics Ltd | Methods for isolating and expanding cells |
| CA3127103A1 (en) * | 2019-01-23 | 2020-07-30 | New York University | Antibodies specific to delta 1 chain of t cell receptor |
| WO2020159368A1 (en) * | 2019-02-01 | 2020-08-06 | Lava Therapeutics B.V. | Novel cd40-binding antibodies |
| CA3136251A1 (en) | 2019-04-08 | 2020-10-15 | Memorial Sloan Kettering Cancer Center | Cd19 antibodies and methods of using the same |
| CA3148588A1 (en) | 2019-08-16 | 2021-02-25 | GammaDelta Therapeutics Limited | Ex vivo gamma delta t cell populations |
| JP2022545196A (ja) | 2019-08-16 | 2022-10-26 | ガンマデルタ セラピューティクス リミテッド | 抗tcrデルタ可変1抗体の治療的使用 |
| ES2943063T5 (en) | 2020-08-14 | 2026-05-05 | Gammadelta Therapeutics Ltd | Multispecific anti-tcr delta variable 1 antibodies |
| KR20230160253A (ko) | 2021-02-17 | 2023-11-23 | 감마델타 테라퓨틱스 엘티디 | 항-tcr 델타 가변 1 항체 |
-
2021
- 2021-08-14 ES ES21756070T patent/ES2943063T5/es active Active
- 2021-08-14 MX MX2023001728A patent/MX2023001728A/es unknown
- 2021-08-14 EP EP23153152.6A patent/EP4218932A3/en active Pending
- 2021-08-14 CA CA3188682A patent/CA3188682A1/en active Pending
- 2021-08-14 BR BR112023002741A patent/BR112023002741A2/pt unknown
- 2021-08-14 SI SI202130032T patent/SI4010082T2/sl unknown
- 2021-08-14 ES ES23187269T patent/ES2993071T3/es active Active
- 2021-08-14 EP EP23187272.2A patent/EP4269445B1/en active Active
- 2021-08-14 PL PL23187269.8T patent/PL4269444T3/pl unknown
- 2021-08-14 PT PT231872698T patent/PT4269444T/pt unknown
- 2021-08-14 WO PCT/IB2021/057509 patent/WO2022034562A1/en not_active Ceased
- 2021-08-14 AU AU2021323512A patent/AU2021323512A1/en active Pending
- 2021-08-14 PL PL21756070.5T patent/PL4010082T5/pl unknown
- 2021-08-14 EP EP23187270.6A patent/EP4265642B1/en active Active
- 2021-08-14 KR KR1020237005145A patent/KR20230083267A/ko active Pending
- 2021-08-14 SI SI202130192T patent/SI4269444T1/sl unknown
- 2021-08-14 EP EP21756070.5A patent/EP4010082B9/en active Active
- 2021-08-14 EP EP23187269.8A patent/EP4269444B1/en active Active
- 2021-08-14 FI FIEP21756070.5T patent/FI4010082T4/fi active
- 2021-08-14 EP EP23187271.4A patent/EP4265643B1/en active Active
- 2021-08-14 IL IL300517A patent/IL300517A/en unknown
- 2021-08-14 EP EP23187273.0A patent/EP4269446B1/en active Active
- 2021-08-14 FI FIEP23187269.8T patent/FI4269444T3/fi active
- 2021-08-14 DK DK23187269.8T patent/DK4269444T5/da active
- 2021-08-14 LT LTEP23187269.8T patent/LT4269444T/lt unknown
- 2021-08-14 LT LTEPPCT/IB2021/057509T patent/LT4010082T/lt unknown
- 2021-08-14 DK DK21756070.5T patent/DK4010082T4/da active
- 2021-08-14 JP JP2023510439A patent/JP7847579B2/ja active Active
- 2021-08-14 PT PT217560705T patent/PT4010082T/pt unknown
- 2021-08-14 CN CN202180069269.3A patent/CN116209456A/zh active Pending
-
2023
- 2023-03-13 CO CONC2023/0003009A patent/CO2023003009A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024506682A5 (cg-RX-API-DMAC7.html) | ||
| JP2023126852A5 (cg-RX-API-DMAC7.html) | ||
| FI3535392T3 (fi) | Immunologisesti havaittavia solupintavariantteja käytettäväksi soluterapiassa | |
| JP2019533450A5 (cg-RX-API-DMAC7.html) | ||
| JP2023515199A5 (cg-RX-API-DMAC7.html) | ||
| JP2025513879A5 (cg-RX-API-DMAC7.html) | ||
| US20220403025A1 (en) | Therapeutic uses of anti-tcr delta variable 1 antibodies | |
| JP7017506B2 (ja) | 系統特異的抗原の阻害のための組成物および方法 | |
| IL295897A (en) | Materials and methods for modulating an immune response | |
| JP2017506636A5 (cg-RX-API-DMAC7.html) | ||
| JP2004528806A5 (cg-RX-API-DMAC7.html) | ||
| US20060003452A1 (en) | Vector packaging cell line | |
| JP2025517657A5 (cg-RX-API-DMAC7.html) | ||
| IL300517A (en) | Multispecific antibodies against variable chain delta 1 on TCR | |
| US20240382521A1 (en) | Methods of engineering immune cells having reduced fratricidal activity | |
| JP2025516377A (ja) | 多重特異性抗体を含む治療薬及び腫瘍治療におけるその使用 | |
| CA3236152A1 (en) | Compositions and methods for erm2 modification | |
| WO2023049926A2 (en) | Fusion polypeptides for genetic editing and methods of use thereof | |
| US20230414755A1 (en) | Methods and compositions relating to genetically engineered cells expressing chimeric antigen receptors | |
| US20240344058A1 (en) | Compositions and methods for bcma modification | |
| US20260083847A1 (en) | T-cell receptors and compositions thereof for targeting mutant ras | |
| Clark et al. | CD nomenclature 2015: human leukocyte | |
| JP2025513894A5 (cg-RX-API-DMAC7.html) | ||
| CN116744963A (zh) | 与表达嵌合抗原受体的经基因工程化的细胞有关的方法和组合物 | |
| Alaverdi | Monoclonal antibodies to mouse cell‐surface antigens |